title: Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
abstract: The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (CML) in 20 predefined countries and regions of Europe. Registration time ranged from 12 to 60 months between January 2008 and December 2013. Median age was 55 years and median observation time was 29 months. Eighty percent of patients were treated first line with imatinib, and 17% with a second-generation tyrosine kinase inhibitor, mostly according to European LeukemiaNet recommendations. After 12 months, complete cytogenetic remission (CCyR) and major molecular response (MMR) were achieved in 57% and 41% of patients, respectively. Patients with high EUTOS risk scores achieved CCyR and MMR significantly later than patients with low EUTOS risk. Probabilities of overall survival (OS) and progression-free survival for all patients at 12, 24 and 30 months was 97%, 94% and 92%, and 95%, 92% and 90%, respectively. The new EUTOS long-term survival score was validated: the OS of patients differed significantly between the three risk groups. The probability of dying in remission was 1% after 24 months. The current management of patients with tyrosine kinase inhibitors resulted in responses and outcomes in the range reported from clinical trials. These data from a large population-based, patient sample provide a solid benchmark for the evaluation of new treatment policies.
authors: Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, IBE, University of Munich, Munich, Germany.
authors: V S
authors: VS
authors: Hoffmann
authors: University of Bologna, Bologna, Italy.
authors: M
authors: M
authors: Baccarani
authors: Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, IBE, University of Munich, Munich, Germany.
authors: J
authors: J
authors: Hasford
authors: Institute of Hematology 'L & A Seragnoli', Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
authors: F
authors: F
authors: Castagnetti
authors: Division of Hematology, AOU Policlinico-OVE, University of Catania, Catania, Italy.
authors: F
authors: F
authors: Di Raimondo
authors: Servicio de Hematología, Hospital Virgen de la Salud, Toledo, Spain.
authors: L F
authors: LF
authors: Casado
authors: Federal State-Funded Institution 'National Research Center for Hematology' of the Ministry of Healthcare of Russian Federation, Moscow, Russian Federation.
authors: A
authors: A
authors: Turkina
authors: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
authors: D
authors: D
authors: Zackova
authors: Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands.
authors: G
authors: G
authors: Ossenkoppele
authors: St Petersburg State Medical University, St Petersburg, Russian Federation.
authors: A
authors: A
authors: Zaritskey
authors: University of Uppsala, Uppsala, Sweden.
authors: M
authors: M
authors: Höglund
authors: University of Uppsala, Uppsala, Sweden.
authors: B
authors: B
authors: Simonsson
authors: Department Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic.
authors: K
authors: K
authors: Indrak
authors: Department of Hematology, University Hospital, Bratislava, Slovakia.
authors: Z
authors: Z
authors: Sninska
authors: Katedra i Klinika Hematologii UJCM, Kraków, Poland.
authors: T
authors: T
authors: Sacha
authors: Royal Liverpool University Hospital, Liverpool, UK.
authors: R
authors: R
authors: Clark
authors: Clinic of Hematology CCS and Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
authors: A
authors: A
authors: Bogdanovic
authors: Department of Hematology and Transplantation, Medical University of Gdansk, Gdansk, Poland.
authors: A
authors: A
authors: Hellmann
authors: Vilnius University Hospital Santariskiu Klinikos and Vilnius University, Vilnius, Lithuania.
authors: L
authors: L
authors: Griskevicius
authors: Munich Cancer Registry, Ludwig-Maximilians-Universitaet, Munich, Germany.
authors: G
authors: G
authors: Schubert-Fritschle
authors: Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Zagreb, Croatia.
authors: D
authors: D
authors: Sertic
authors: INSERM CIC 1402, CHU Poitiers, Poitiers, France.
authors: J
authors: J
authors: Guilhot
authors: Riga East Clinical University Hospital, Riga, Latvia.
authors: S
authors: S
authors: Lejniece
authors: Department of Hematology, University Clinical Centre, Ljubljana, Slovenia.
authors: I
authors: I
authors: Zupan
authors: Klinikum Wells-Grieskirchen, Wells, Austria.
authors: S
authors: S
authors: Burgstaller
authors: Helsinki University Central Hospital and Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland.
authors: P
authors: P
authors: Koskenvesa
authors: Tartu University Hospital, Tartu, Estonia.
authors: H
authors: H
authors: Everaus
authors: The Karaiskakio Foundation, Nicosia, Cyprus.
authors: P
authors: P
authors: Costeas
authors: Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, IBE, University of Munich, Munich, Germany.
authors: D
authors: D
authors: Lindoerfer
authors: Department of Oncology and Hematology, Hematology Unit, St Orsola University Hospital, Bologna, Italy.
authors: G
authors: G
authors: Rosti
authors: III. Medizinische Klinik, University of Heidelberg at Mannheim, Mannheim, Germany.
authors: S
authors: S
authors: Saussele
authors: Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
authors: A
authors: A
authors: Hochhaus
authors: III. Medizinische Klinik, University of Heidelberg at Mannheim, Mannheim, Germany.
authors: R
authors: R
authors: Hehlmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D012042:Registries; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult